

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761071Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: October 30, 2018

TO: Administrative file for BLA 761071

FROM: Nina Ton, Regulatory Health Project Manager
Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs

SUBJECT: Officer/Employee List for BLA 761071

APPLICATION/DRUG: BLA 761071 Hyrimoz (adalimumab-adaz) for subcutaneous injection

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Absar, Mohammad (Abir)
Adeleye, Adewale
An, Yanming
Bonapace, Charles
Borders-Hemphill, Vicky
Candauchacon, Maria
Ceresa, Carrie
Chiang, Gary
Coyne, Laurence
Dasgupta, Arindam
Dinatale, Miriam
Fitzgerald, Kathleen
Fritsch, Kathleen
Goodwin, Andrew
Hsu, Chih-Jung
Jafari, Ladan
Jones, Brett
Lafleur, Philip
Lee, Jessica
Levin, Gregory
Ly, Anh-Thy
Marathe, Anshu
Mena-Grillasca, Carlos
Newman, Tyree

Nikolov, Nikolay
Qiu, Zhihao Peter
Radden, Erica
Rajabiabhari, Mohsen
Rothwell, Rebecca
Sarai, Aman
Seymour, Sally
Shanks, Michael
Ton, Phuong Nina
Wang, Tianhua
Williams, Marcia Britt